Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Polo-like kinases mediate cell survival in mitochondrial dysfunction.

Matsumoto T, Wang PY, Ma W, Sung HJ, Matoba S, Hwang PM.

Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14542-6. doi: 10.1073/pnas.0904229106. Epub 2009 Aug 11.

2.

Reciprocal activation between PLK1 and Stat3 contributes to survival and proliferation of esophageal cancer cells.

Zhang Y, Du XL, Wang CJ, Lin DC, Ruan X, Feng YB, Huo YQ, Peng H, Cui JL, Zhang TT, Wang YQ, Zhang H, Zhan QM, Wang MR.

Gastroenterology. 2012 Mar;142(3):521-530.e3. doi: 10.1053/j.gastro.2011.11.023. Epub 2011 Nov 19.

PMID:
22108192
3.

Polo-like kinase 2 activates an antioxidant pathway to promote the survival of cells with mitochondrial dysfunction.

Li J, Ma W, Wang PY, Hurley PJ, Bunz F, Hwang PM.

Free Radic Biol Med. 2014 Aug;73:270-7. doi: 10.1016/j.freeradbiomed.2014.05.022. Epub 2014 Jun 2.

4.

Proliferation state and polo-like kinase1 dependence of tumorigenic colon cancer cells.

Francescangeli F, Patrizii M, Signore M, Federici G, Di Franco S, Pagliuca A, Baiocchi M, Biffoni M, Ricci Vitiani L, Todaro M, De Maria R, Zeuner A.

Stem Cells. 2012 Sep;30(9):1819-30. doi: 10.1002/stem.1163.

6.

Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536.

Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, Ferenc V, Schuch K, Mirkina I, Horny HP, Pickl WF, Müllauer L, Willmann M, Valent P.

Haematologica. 2011 May;96(5):672-80. doi: 10.3324/haematol.2010.031328. Epub 2011 Jan 17.

7.

Efficient inhibition of human colorectal carcinoma growth by RNA interference targeting polo-like kinase 1 in vitro and in vivo.

Xu WJ, Zhang S, Yang Y, Zhang N, Wang W, Liu SY, Tian HW, Dai L, Xie Q, Zhao X, Wei YQ, Deng HX.

Cancer Biother Radiopharm. 2011 Aug;26(4):427-36. doi: 10.1089/cbr.2010.0922. Epub 2011 Jul 28.

PMID:
21797676
9.

Phosphorylation of synucleins by members of the Polo-like kinase family.

Mbefo MK, Paleologou KE, Boucharaba A, Oueslati A, Schell H, Fournier M, Olschewski D, Yin G, Zweckstetter M, Masliah E, Kahle PJ, Hirling H, Lashuel HA.

J Biol Chem. 2010 Jan 22;285(4):2807-22. doi: 10.1074/jbc.M109.081950. Epub 2009 Nov 4.

10.

Intravenous liposomal delivery of the short hairpin RNAs against Plk1 controls the growth of established human hepatocellular carcinoma.

Deng H, Jiang Q, Yang Y, Zhang S, Ma Y, Xie G, Chen X, Qian Z, Wen Y, Li J, Yang J, Chen L, Zhao X, Wei Y.

Cancer Biol Ther. 2011 Feb 15;11(4):401-9. Epub 2011 Feb 15.

PMID:
21150280
11.

Polo-like kinase 1 inhibits the activity of positive transcription elongation factor of RNA Pol II b (P-TEFb).

Jiang L, Huang Y, Deng M, Liu T, Lai W, Ye X.

PLoS One. 2013 Aug 16;8(8):e72289. doi: 10.1371/journal.pone.0072289. eCollection 2013.

12.

Phosphorylation of TCTP as a marker for polo-like kinase-1 activity in vivo.

Cucchi U, Gianellini LM, De Ponti A, Sola F, Alzani R, Patton V, Pezzoni A, Troiani S, Saccardo MB, Rizzi S, Giorgini ML, Cappella P, Beria I, Valsasina B.

Anticancer Res. 2010 Dec;30(12):4973-85.

PMID:
21187478
14.

PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.

Tan J, Li Z, Lee PL, Guan P, Aau MY, Lee ST, Feng M, Lim CZ, Lee EY, Wee ZN, Lim YC, Karuturi RK, Yu Q.

Cancer Discov. 2013 Oct;3(10):1156-71. doi: 10.1158/2159-8290.CD-12-0595. Epub 2013 Jul 25.

15.

Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.

Gerster K, Shi W, Ng B, Yue S, Ito E, Waldron J, Gilbert R, Liu FF.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):253-60. doi: 10.1016/j.ijrobp.2009.11.027.

PMID:
20394857
16.

Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation.

Koida N, Ozaki T, Yamamoto H, Ono S, Koda T, Ando K, Okoshi R, Kamijo T, Omura K, Nakagawara A.

J Biol Chem. 2008 Mar 28;283(13):8555-63. doi: 10.1074/jbc.M710608200. Epub 2008 Jan 3.

17.

Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.

Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE.

Mol Cancer Ther. 2009 Nov;8(11):3024-35. doi: 10.1158/1535-7163.MCT-09-0365. Epub 2009 Nov 3.

18.

Calcipotriol affects keratinocyte proliferation by decreasing expression of early growth response-1 and polo-like kinase-2.

Kristl J, Slanc P, Krasna M, Berlec A, Jeras M, Strukelj B.

Pharm Res. 2008 Mar;25(3):521-9. Epub 2007 Aug 2.

PMID:
17671831
19.

Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation.

Liu XS, Song B, Elzey BD, Ratliff TL, Konieczny SF, Cheng L, Ahmad N, Liu X.

J Biol Chem. 2011 Oct 14;286(41):35795-800. doi: 10.1074/jbc.C111.269050. Epub 2011 Sep 2.

20.

Cancer Osaka thyroid (Cot) phosphorylates Polo-like kinase (PLK1) at Ser137 but not at Thr210.

Wu B, Jiang P, Mu Y, Wilmouth RC.

Biol Chem. 2009 Dec;390(12):1271-7. doi: 10.1515/BC.2009.141.

PMID:
19804365
Items per page

Supplemental Content

Write to the Help Desk